
    
      Study design:

      Prospective observational study comparing ablative measures as TACE or SIRT with surgery/RFA
      and with peptide receptor radio-therapy in patients with advanced well-differentiated
      neuroendocrine tumors with lymph node or distant metastases (N1, M1) Prospective evaluation
      Primary end points: time to progression Secondary end points: survival, quality of life
      (EORTC-QLQ30), weight, time of hospitalization, Karnofsky index) Non-randomized cohort study
      Number of patients needed in all groups: 70 per group, 210 overall Evaluation of response to
      therapy every 3-6 months by imaging, clinical status, weight, quality of life,
      Karnofsky-index Cross-over allowed if therapy changes
    
  